Physician profile
Jun Ting Liu
NPI 1366566184
$915.61
in general payments reported to CMS, 2019-2025
11 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.24 · 2022: $535 · 2023: $89.27 · 2024: $41.49 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.53 | 2021-2023 | Ozempic |
| Abbvie INC. | $249.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.33 | 2022-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $62.34 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $51.07 | 2023-2025 | Trelegy Ellipta |
| Alnylam Pharmaceuticals INC. | $33.41 | 2025 | Givlaari |
| Agios Pharmaceuticals, INC. | $32.73 | 2025 | Pyrukynd |
| Lilly USA, LLC | $24.58 | 2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.43 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $20.67 | 2021 | |
| Pfizer INC. | $15.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Ting Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.